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ABSTRACT 
 
Transcription factors are proteins that are involved in the regulation of gene expression and are 
responsible for the tight control of transcription allowing a cell to react to changes in its 
environment. Transcription factors are thus highly regulated by a variety of mechanisms which 
include phosphorylation. Forkhead box P2 (FOXP2) is a transcription factor expressed in multiple 
tissues during embryonic development. FOXP2 like other FOX proteins contains a DNA binding 
domain known as the forkhead domain (FHD). The effect of phosphorylation of serine 557 in the 
FHD on the structure and DNA binding was done using a glutamate mutant (to mimic 
phosphorylation) and an alanine mutant (as a control). Structural characterisation was performed 
using size exclusion chromatography (SEC), intrinsic fluorescence and far-UV circular dichroism. 
The effect of phosphorylation on DNA binding was observed using electrophoretic mobility shift 
assay (EMSA) and isothermal titration calorimetry (ITC). Far-UV circular dichroism and intrinsic 
fluorescence of the mutants and wild type did not reveal any significant secondary or tertiary 
structural changes. SEC however revealed a decrease in dimerisation propensity in the Ser557 
mutants when compared the wild type (WT). EMSA revealed that DNA binding of S557E is only 
observed at protein concentrations 40 times in excess of the DNA. DNA binding of the WT and 
S557A mutants is observed at 5 times and 20 times excess protein respectively. However, using 
ITC no DNA binding is observed for either S557E or S557A FOXP2 FHD. Thus, it is possible 
that phosphorylation of serine 557 in the FOXP2 FHD could be a mechanism for inactivation of 
FOXP2. 
[257 words] 
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CHAPTER 1       Introduction 
 
1.1. Transcription 
Transcription factors (TF) are proteins that are involved in the regulation of gene 
expression. These proteins are responsible for the tight control of transcription allowing a 
cell to react to even slight changes in environment in an instant. This is achieved by 
allowing activation or repression of multiple genes (Huffman & Brennan, 2002).  
In eukaryotes, RNA polymerase II transcribes DNA forming mRNA. RNA polymerase 
forms a complex with multiple general transcription factors on the DNA which is known 
as the basal transcription complex or the preinitiation complex (PIC) (Fig 1.1). 
Transcription is initiated when the PIC forms on specific regions of the DNA known as the 
promoter (Van Dyke et al, 1988; Roeder, 1991; Conaway & Conaway, 1993; Grünberg & 
Hahn, 2013). General transcription factors are responsible for the transcription of 
housekeeping genes which are expressed in order to maintain basic cellular function 
(Pedersen et al, 1999). In addition to general transcription factors there are other TFs that 
are responsible for transcription activation or repression of facultative genes. Facultative 
genes are differentially expressed depending on the tissue type and in response to stimuli 
(Burley, 1997). 
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Fig 1.1. The preinitiation complex or basal transcription complex that forms on the 
promotor and initiates transcription. The TATA binding protein (TBP) binds the 
promotor followed by the other general transcription factors (TFIIA, TFIIB, TFIIF, 
TFIIE, TFIIE and TFIIH) and RNA polymerase II (Roeder, 1996). 
 
1.2. Transcription factors 
TFs tend to have multiple domains which generally facilitate DNA binding and protein-
protein interactions. The DNA binding domains are involved in specifically binding 
regulatory sites on the DNA to regulate expression of specific genes. TFs either activate or 
repress transcription. This often occurs via protein-protein interactions with transcription 
machinery (Latchman, 1997).  There are thousands of TFs classed into many families based 
on their DNA binding domains. Some examples of these domains include helix-turn-helix 
(HTH), zinc finger (ZF), leucine zipper (LZ), winged helix-turn-helix (W-HTH) and helix-
loop-helix (Burley, 1997).  
 
 The classical HTH motif (Fig 1.2) has three alpha helices orientated in a triangular like 
shape. The turn between helix 2 and helix 3 is typically sharp and often well conserved. 
Helix 3 is inserted into the major groove during DNA binding. There are many variations 
of the basic HTH motif one of which is the winged-helix-turn-helix (W-HTH). The major 
difference between the HTH and W-HTH is the presence of a β-strand hairpin wing on the 
C-terminal end. The W-HTH, like the HTH motif, binds DNA by insertion of helix 3 into 
3 
 
the major groove. The wing however may make additional DNA contacts with the minor 
groove (in some cases)  (Aravind et al, 2005). 
 
 
Fig 1.2. A: The major and minor groove of B-DNA. B: Schematic diagram of the helix-
turn-helix. C: Schematic diagram of the winged-helix-turn-helix (W-HTH) motifs. 
The helices are displayed as blue cylinders and the β-strand hairpin in green. In the HTH 
and W-HTH helix 3 is inserted into the major groove of the DNA. Image adapted from 
(Aravind et al, 2005). 
 
1.3. Regulation of transcription 
Regulation of the transcription of genes is very important. It is this differential regulation of 
genes that allows different cell types to form in multi-cellular organisms. Regulation of 
transcription is achieved by regulatory DNA binding sites, transcription activators and 
repressors.  
 
1.3.1. DNA binding 
Transcription is initiated when the PIC forms on the promoter region of DNA (Fig 1.1). 
Common promotors in eukaryotes are the TATA box (found 25 to 30 bp upstream of the 
transcription start site), initiator sequence (which spans the transcription start site) and the 
downstream promotor element (which is located 25 bp downstream of the transcription start 
site) (Fig 1.3). First the TBP (TATA box binding protein) binds directly to promotor or 
proximal promotor elements after which several other components of the PIC assemble, 
including polymerase II, at the promotor and spans from position -30 to +30 (Sainsbury et 
A B C 
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al, 2015). Eukaryotes contain regulatory regions of DNA known as enhancers or silencers 
to which specific TFs bind in order to regulate transcription. TFs which act as activators 
bind enhancer regions on the DNA whereas TFs which act as repressors bind the silencer 
regions on the DNA. Neither transcription activators nor repressors directly bind the 
promotor but they may interact with the PIC which forms at the promotor. These enhancer 
and silencer sites in the DNA can be found kilobases before and after the transcription start 
sites (Fig 1.3). These regulatory regions of DNA contain binding sites for multiple TFs and 
thus the control of transcription is also dependent on the types of TFs present in the cell at 
any given time (Pedersen et al, 1999).  
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Fig 1.3. A: Structure of RNA polymerase II promoter. The structural gene (purple) is transcribed when 
the transcription initiation complex forms at the promoter region (green) Common eukaryotic promoters 
are indicated in grey. Enhancer/ silencer sites (blue) are bound by TFs which either activate or repress 
transcription of specific genes. B: Transcription factors bound to the preinitiation complex and 
enhancer/ silencers. The preinitiation complex (PIC, blue) is bound to the promotor. The DNA is looped 
by a DNA bending protein (purple). Activators (A, green) bound to enhancers either interact with the PIC 
directly or indirectly through co-activators (grey). Repressors (R, orange) bind silencers and either prevent 
activators from binding enhancer sites or prevent them from binding the PIC. 
 
 
 
A 
B 
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1.3.2. Transcription activators and repressors 
Transcription activation is defined as the increase in the rate of gene expression whereas 
transcription repression is defined as the decrease in the rate of gene expression. The manner 
in which TFs either act as repressors or activators varies. TFs function as transcription 
activators by interacting with either the PIC or other co-activators (Fig 1.3). They activate 
transcription by either increasing the rate of the basal transcription complex formation or 
enhancing its level of activity (Roberts, 2000). Many TFs act as transcriptional repressors. 
The first mechanism of transcriptional repression is competitive binding to the 
transcriptional activator’s DNA binding site (Fig 1.4). Transcription repression is 
sometimes achieved by binding to the activation domain on a transcription activator or by 
interaction (either directly or indirectly) with members of the basal transcription complex. 
Transcription repressors can also bind to their own specific regulatory DNA sequences 
(Cowell, 1994; Latchman, 1997).  Some TFs can even act as both activators and repressors 
(Sharrocks, 2001). 
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Fig 1.4. Mechanisms of repression of gene expression by transcription factors. A:  Transcription of the 
gene is active when the activator (A) is bound to enhancer region of the DNA. B: Transcription is repressed 
when the repressor (R) competitively binds the activator’s (A) DNA binding site. C: The repressor (R) 
binds the activator (A) preventing the activator from binding the DNA, therefore repressing gene 
expression. D: The repressor (R) directly binds the activator (A) or the preinitiation complex thereby 
inhibiting activation of gene expression. E: The repressor (R) binds to a specific inhibitory DNA sequence 
(silencer) preventing gene expression. 
 
1.3.3.  Regulation of transcription factors 
In order for cells to respond to stimuli and changes in environment, differential expression 
of specific genes is required. This is generally achieved through signal transduction 
pathways, which through multiple proteins, relay information from the cell’s surface to the 
nucleus. TFs are generally the end targets of these pathways as they are responsible for 
regulation of gene expression (Tootle & Rebay, 2005).  Since TFs are responsible for the 
tight regulation of gene expression they are, themselves highly regulated. Regulation of TFs 
occurs by a variety of mechanisms of which binding of ligands, interactions with other 
proteins or post translational modifications are examples (Latchman, 1997).  
 
 
A 
B 
C 
D 
E 
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1.3.4. Post translational modifications 
Post translational modification (PTM) of TFs is one of the ways in which TFs with highly 
similar binding sequences can regulate very distinct genes. TFs have been shown to undergo 
many types of PTMs. These include phosphorylation, acetylation, ubiquintation, 
glycosylation and sumoylation (Benayoun & Veitia, 2009). PTMs of TFs, either individually 
or in combination, have been shown to influence protein-protein interactions, DNA-
interactions, cellular localisation, activity and stability of TFs (Tootle & Rebay, 2005). PTMs 
have been shown to occur on multiple sites on a protein (multisite modification). This is 
important as multiple pathways can converge on the same target TF via different 
modifications. These different modification patterns present on the target TF at any given 
time can cause different structural and functional changes (Benayoun & Veitia, 2009; Tootle 
& Rebay, 2005) 
 
Glycosylation is the addition of O-linked β-N-acetylglucosamine to the hydroxyl group of 
serine and threonine residues. Serine and threonine residues can also be phosphorylated post 
translationally. Phosphorylation is the addition of a phosphate group to these residues. 
Phosphorylation and glycosylation therefore acts on the same residues and in fact may act 
competitively (Vosseller et al, 2001).  Lysine residues however are the target for acetylation, 
sumoylation and ubiquitination. Acetyltransferase mediates the transfer of an acetyl group to 
specific lysine residues (Bannister et al, 2000).  Sumoylation is the attachment of a small 
protein, known as Small ubiquitin like modifier (SUMO), to specific lysine residues. 
Ubiquitination like sumoylation is the addition of ubiquitin to specific amino acid residues 
and is catalysed in a multiple step process (Geiss-Friedlander & Melchior, 2007). 
Sumoylation, ubiquitination, acetylation, glycosylation and phosphorylation of specific 
residues affect the activity, location, structure and stability of their targets (Gill, 2004; Verger 
et al, 2003) 
 
 
 
 
9 
 
1.3.5. Phosphorylation 
One of the most studied PTMs is phosphorylation as it is a regulatory mechanism for a wide 
variety of proteins including TFs. Phosphorylation is the esterfication of a phosphate group 
to the hydroxyl group of either tyrosine, serine or threonine residues, which is facilitated by 
kinases (Tarrant & Cole, 2009). Kinases generally phosphorylate residues by transferring the 
γ- phosphate from high energy donor molecules such as adenosine triphosphate and 
guanosine triphosphate. Kinases fall into two very broad classes (S/T kinases and Y kinases) 
(Tootle & Rebay, 2005). 
 
 Phosphorylation generally acts as a regulatory mechanism for proteins, including TFs, in 
two ways. Firstly, the addition of the charged phosphate group can induce local and long 
range conformational changes in proteins. This is often due to alteration of electrostatic 
interactions and hydrophobicity of specific regions on proteins. The change in conformation 
is a regulatory mechanism as this may change the nature of the binding sites therefore 
affecting protein-protein and protein-DNA interactions that occur (Johnson & Barford, 
1993). The second way in which phosphorylation regulates protein activity is by steric and 
electrostatic repulsion, due the addition of the negative charge, which blocks the proteins’ 
active sites or binding sites without any conformational changes occurring (Johnson & 
Barford, 1993). Many TFs such as members of the Ets (E26 transformation-specific) family 
(Wasylyk et al, 1997), NF-IL6 and STAT3 (Akira, 1997) have been shown to be regulated 
by phosphorylation in this way.  
 
1.4.    FOX proteins 
 
FOX (forkhead box) proteins are a family of TFs which contain a highly conserved winged 
helix domain (called the forkhead domain), which is typically involved in DNA binding. 
Despite the conserved forkhead domain (FHD), FOX proteins are functionally diverse. FOX 
proteins have been shown to be involved in embryonic development in various tissues (Shu 
et al, 2007), the immune system (Koh et al, 2009), metabolism (Friedman & Kaestner, 2006) 
and have been implicated in cancer (Sharma et al, 2005). 
10 
 
Fig 1.5. displays the first solved crystal structure of a FOX FHD: that of the FOXA3 forkhead 
domain (FHD) bound to DNA (Clark et al, 1993). This can be considered a generic model 
for all FOX FHDs. The FOX forkhead domain is a W-HTH motif and is between 90 and 100 
residues in length. The FHD comprises of three α-helices (helix 1, helix 2 and helix 3) and 
two flanking loops which form wing like structures (wing 1 and wing 2) (Friedman & 
Kaestner, 2006; Clark et al, 1993). These winged regions are the least conserved regions of 
the FHD. The FHD binds DNA by insertion of helix 3 into the major groove. Helix 3 is 
highly conserved in all FOX proteins (Friedman & Kaestner, 2006; Clark et al, 1993). 
 
Fig 1.5. FOXA3 forkhead domain bound to DNA. Helix 3 is wedged into the major groove 
of the DNA (grey). PDB ID: 1VTN (Clark et al. 1993). Image rendered with the PyMOL 
Molecular Graphics System, Version 1.8 Schrödinger, LLC.  
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1.4.1. FOXP subfamily 
FOX proteins are arranged into various subfamilies (A-S) based on different structural 
characteristics. The four members of the FOXP subfamily are distinguished from other FOX 
proteins as the FHD is found at the C-terminal rather than the N-terminal end (Chu et al, 2011). 
In addition to the FHD, the FOXP proteins also share additional similar structural motifs which 
include a glutamine-rich region, a zinc finger and a leucine zipper which are unique to the 
FOXP subfamily (Fig 1.6) (Wang et al, 2003). The glutamine rich region has been shown in 
other TFs to function as a transcriptional activation/ repression domain (Shu et al, 2001; Wang 
et al, 2003). The leucine zipper and zinc finger motifs have been implicated in homo and 
heterodimer formation of the full length FOXP proteins (Wang et al, 2003).  
 
Fig 1.6. Schematic diagram depicting the various domains of FOXP proteins. The 
polyglutamine region (grey), zinc finger (purple), leucine zipper (blue), the forkhead domain 
(green) and acid rich tail (orange). FOXP2 numbering is used. 
 
1.2.1.1. FOXP function 
The four members of the FOXP subfamily display diverse functions. FOXP1 has been shown 
to be involved in tumour suppression (Banham et al, 2001). FOXP3, one of the more studied 
members has been implicated in regulation of the immune system (Koh et al, 2009). FOXP4, 
the least studied member, has been found to be expressed in multiple tissues within the heart, 
lungs, kidneys, testis, brain and liver (Teufel et al, 2003). 
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FOXP2 is expressed in intestinal, neural and cardiovascular tissues during embryonic 
development (Shu et al, 2001). The importance of FOXP2 was first recognised when the 
R553H mutation in its forkhead domain was discovered. The mutation was discovered in a 
family, known as the KE family, suffering from a speech disorder classified as verbal 
dyspraxia. Verbal dyspraxia is defined as the inability to sequence mouth movements resulting 
in difficulty with pronunciation. In addition to verbal dyspraxia, members of the KE family, 
despite displaying close to normal nonverbal IQ, also display defects of written language and 
receptive linguistic skills (Fisher & Scharff, 2009). 
 
1.2.1.2. FOXP structure 
Members of the FOXP subfamily, like other FOX proteins, bind DNA by insertion of helix 3 
into the DNA major groove. FOXPs however, unlike other FOX proteins, have the ability to 
form a domain swapped dimer with the FHD. In addition to the formation of a domain swapped 
dimer of the FHD, the full length FOXP proteins may also form homo and heterodimers (Wang 
et al, 2003; Li et al, 2004). This is mediated by the leucine zipper/ zinc finger region. 
 
In domain swapping of FOXP2, FOXP3 and FOXP1, helix 3, strand 2 and strand 3 are swapped 
by two FOXP2 monomers. Domain swapping of the FHD is made possible due to the extension 
of the turn connecting helix 2 and helix 3 (Bandukwala et al, 2011; Chu et al, 2011; Stroud et 
al, 2006). There are multiple residues that interact along the hydrophobic dimer interface of  
the FOXP2 domain swapped dimer which include Tyr509, Tyr531, Tyr540, Trp533, Trp548, 
Phe507, Phe534, Phe538 and Phe541 from both monomers (Stroud et al, 2006). It is possible 
that the FOXP2 domain swapped dimer may simultaneously bind two separate DNA strands, 
due to the proximity of the two DNA binding surfaces of the domain swapped dimer. It has 
been postulated that the FOXP2 domain swapped dimer may loop DNA or even mediate 
interchromosomal contacts in this way (Stroud et al, 2006). In Fig 1.7 the domain swapped 
dimer and monomer of the FOXP2 FHD are displayed (PDB ID: 2A07). The main difference 
between the dimer and the monomer is that in the dimer helix 2 is extended to form the hinge 
region.  
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Fig 1.7. The FOXP2 FHD domain swapped dimer (A) and monomer (B). One monomer of 
the domain swapped dimer is displayed in grey. The dimer is formed by the interchange of 
helix 3, strand 1 and strand 2 (PDB ID: 2A07)(Stroud et al, 2006). Image rendered with PyMOL 
Molecular Graphics System, Version 1.8 Schrödinger, LLC. 
 
1.2.1.3. FOXP2 DNA binding and sequence specificity 
The FOXP2 FHD has been shown to bind DNA in the dimeric and monomeric form. As with 
other FOX proteins the monomeric FHD of FOXP2 interacts with DNA by inserting helix 3 
into the major groove. The main DNA interactions formed by the monomeric FHD, as 
determined from the crystal structure (PDB ID: 2A07) occur through Asn550, Arg553 and 
His554. Asn550 and His554 from direct hydrogen bonds with the DNA while Arg553 forms a 
water mediated hydrogen bond with the DNA bases. Hydrogen bonds to the DNA phosphate 
backbone are formed by Ser557, Thr547, Arg504, Trp573, Tyr509, Arg583 and Arg584. In 
addition to these hydrogen bonds various residues also form extensive van der Waals 
interactions with the DNA. Certain aromatic and hydrophobic residues from helix 1 and helix 
3 interact with the DNA stabilising the DNA protein interaction (Stroud et al, 2006). 
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As the forkhead domain of FOX proteins is so highly conserved, it is predicted that FOX 
proteins have similar DNA sequences to which they will bind. The general FOX consensus 
sequence is 5’ [A/G][C/T][A/C]AA[C/T]A 3’ (Carlsson & Mahlapuu, 2002). Regions in the 
FHD such as wing 1 and wing 2 as well as helix 3 confer DNA binding specificity. FOX 
proteins including FOXA3 utilise the wing 1 and wing 2 regions to extensively bind to the 
DNA minor groove and backbone. As the FOXP2 forkhead domain has shorter wing 1 and 
wing 2 regions, there are limited DNA contacts. It has been postulated that this could result in 
a decrease in binding affinity of FOXP2 compared to some other FOX proteins (Stroud et al, 
2006). Per the crystal structure, FOXP2 utilises many van der Waals forces and fewer hydrogen 
bonds to make contacts in the major groove compared to other FOX proteins, which could 
allow the FOXP2 FHD more flexibility in terms of DNA binding sequences (Stroud et al, 
2006). The core binding sequence specifically for FOXP2 was defined as 5’ A[C/T]AAATA 
3’ (Wang et al, 2003). More recently however, a cognate sequence was determined by Nelson 
et al, (2013), which is 5’-TGTTTAC-3’.   
 
1.5.  Phosphorylation of FOX proteins 
Phosphorylation has been studied in multiple members of the FOX protein family, and most 
extensively in the FOXO subfamily.  FOXO proteins have been shown to be phosphorylated 
by ATK/protein kinase B (PKB) at specific sites, in multiple domains including the FHD, in 
vivo. When these ATK/PKB sites are phosphorylated, FOXOs become susceptible to further 
phosphorylation by casein kinase-1 (Biggs et al, 1999). Phosphorylation, in vivo, of a residue 
in the wing 2 region of the FOXO FHD, results in a decrease in DNA binding affinity due to 
the addition of the negative charge in this basic region (Zhang et al, 2002). In addition, 
phosphorylation of residues in the nuclear localisation sequence, found adjacent to the FHD, 
prevents the import of FOXO into the nucleus. This occurs because the phosphorylated FOXO 
can bind the protein 14-3-3 which shields the NLS sequence from nuclear import proteins 
(Brunet et al, 1999). FOXOs have also been shown to be phosphorylated by additional kinases 
and this phosphorylation alters DNA binding (Obsil & Obsilova, 2008).  Other members of the 
FOX family have been shown to be subject to phosphorylation in vivo including FOXP3 (Nie 
et al, 2013), FOXC2 (Berry et al, 2005) and FoxM1 (Chen et al, 2009).  
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1.6.  Possible phosphorylation of FOXP2 
As mentioned previously the FHD binds DNA by inserting helix 3 into the major groove of 
the DNA. The interaction is mediated by multiple hydrogen bonds and Van der Waals 
interactions. There is a highly-conserved serine in most FOX FHDs (Fig 1.8) found on the C-
terminal end of helix 3, in FOXP2 this is Ser557. This serine residue has been shown to be 
phosphorylated in some FOX proteins which include FOXA3 (Shiromizu et al, 2013), FOXO3 
(Lehtinen et al, 2006) and FoxO1(Brent et al, 2008).  In FOXA3 Ser172 was identified as a 
phosphorylation site using mass spectrometry in colorectal cancer cells (Shiromizu et al, 
2013). In addition to this, in FOXO3, Ser215 (Lehtinen et al, 2006) and in FoxO1, Ser218 
(Brent et al, 2008) have been shown to be phosphorylated in vivo. The role of phosphorylation 
of this serine residue in FOXA3 and FOXO3 however, has not been determined. In FoxO1 
mammalian Ste20-like kinase 1 phosphorylates four serine residues in the FHD, one of which 
is Ser215 which corresponds to Ser557 in FOXP2. The phosphorylation of these residues 
completely disrupts DNA binding of FoxO1 in vitro (Brent et al, 2008). In FOXP2 it is 
unknown if Ser557 is a phosphorylation site. However, given its conservation across all 
members of the FOX family and the fact that the serine in this position in other family members 
has been shown to be phosphorylated, Ser 557 can be considered as a likely phosphorylation 
site. In the crystal structure solved by Stroud et al, (2006) (PDB ID: 2A07) Ser557 makes a 
hydrogen bond to the DNA backbone (Fig 1.10A). If Ser557 in FOXP2 is phosphorylated, it 
is currently unknown which kinase may be responsible for its phosphorylation, and 
furthermore its role when phosphorylated is unknown. 
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Fig 1.8. Multiple sequence alignment of the FHD of multiple FOX proteins. Ser557 is highlighted in 
blue in FOX proteins where it has not been shown to be phosphorylated or in green in proteins where it is 
known to be phosphorylated. The secondary structure is represented by the coloured bar below and the 
helices (H), strands (S) and wings (W) are indicated. Multiple sequence alignment done using T-Coffee 
(Notredame et al, 2000; Di Tommaso et al, 2011). 
 
Phosphorylation of Ser557 would result in three additional oxygen atoms. As the pKa of the 
phosphate group is 5.7 (Śmiechowski, 2010)  two of the oxygen atoms will be negatively 
charged at physiological pH. The effect of phosphorylation could therefore result in hydrogen 
bonds forming at the new hydrogen bond acceptor sites (Fig 1.9). Alternatively, the additional 
negative charge after phosphorylation could hinder DNA binding because of electrostatic 
repulsion and steric hindrance.  
To determine what effect phosphorylated Ser557 will have on the structure and function of the 
FOXP2 FHD, a phosphomimetic was used in this study. A phopshomimetic is the mutation of 
a potentially phosphorylated amino acid (serine, threonine or tyrosine) to a charged amino acid 
such as aspartate or glutamate in order to mimic the phosphorylated residue. Phosphomimetics 
have been used successfully to mimic the phosphorylation of serine, threonine and even 
tyrosine (Lowy, 1996 and Potter and Hunter, 1998). The use of aspartate and glutamate to 
mimic phosphorylation is not without challenges. For instance, there is a size difference 
between the phosphate group and the carboxylate group of aspartate and glutamate as well as 
two rather than three additional oxygens. This means that in many instances using aspartate 
and glutamate to mimic phosphorylated residues may not work due to differences in bulk and 
charge.  
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Fig 1.9. The structure of aspartate, glutamate and phosphorylated serine (www.emolecules.com). 
 
In this study for these reasons a S557E (Fig 1.10C) mutant was used to mimic phosphorylation 
of Ser557. Glutamate was chosen rather than aspartate as it is structurally like a phosphoserine 
as it contains an extra carbon making it a similar length to phosphoserine. Glutamate has a pKa 
of approximately 4, therefore it will be negatively charged like phosphoserine at pH 7.5 
(physiological).  A S557A mutant was also made to act as a control (Fig 1.10B). The purpose 
of the alanine control is to ensure that any changes observed between the WT (Fig 1.10A) and 
phosphomimetic are due to changes in charge and bulk and not because of the disruption of 
protein structure or function due to the mutation (Tarrant & Cole, 2009). A phosphomimetic 
was used rather than phosphorylating Ser557 because the kinase that may phosphorylate this 
serine residue is unknown and it would be challenging to ensure that only Ser557 becomes 
phosphorylated. 
 
Glutamate Phosphoserine Aspartate 
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Fig 1.10. The structure of the FOXP2 FHD (PDB ID: A207) bound to DNA showing the WT, 
phosphorylated serine and the two serine mutants. The surface charge (red is negative and blue is 
positive) at position 557 is indicated in the panel at the bottom right of each structure and circled in black. 
A: Ser557 is shown and the hydrogen bonds are displayed as blue dashes. B: S557A mutant bound to DNA.  
C: S557E mutant bound to DNA. D: WT bound to DNA with Ser557 phosphorylated. The increase in 
negative charge and bulk in the phosphorylated WT is clear. The S557E mutant is similar to the 
phosphorylated WT however the smaller size of the residue and decreased charge is notable. The mutants 
were predicted using the wild type crystal structure (2A07) (Stroud et al, 2006). Cartoon Image rendered 
with PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC. Surface charge Image rendered 
with Chimera 1.7 (Pettersen et al, 2004) 
A B 
C D 
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1.7. Main aim 
The aim is to use phosphomimetics to determine the effect of phosphorylation of Ser557 on 
the structure and DNA binding of the FOXP2 forkhead domain. 
 
1.8.  Objectives 
To produce the phosphomimetic (S557E) and the control (S557A) FOXP2 FHD using site 
directed mutagenesis. 
 
To express the wild type and various mutant FOXP2 FHDs using the pET-11a plasmid and 
to purify the respective proteins using His-tag affinity chromatography. 
 
To investigate the effect of the phosphomimetic of Ser557 on the equilibrium between the 
monomer and dimer of the FOXP2 FHD using size exclusion chromatography. 
 
To investigate the effect of the phosphomimetic of Ser557 on the secondary structure of 
the FOXP2 FHD using far-UV circular dichroism.  
 
To investigate the effect of the phosphomimetic of Ser557 on the tertiary structure of the 
FOXP2 FHD using intrinsic tryptophan fluorescence.  
 
To investigate the effect of the phosphomimetic of Ser557 on DNA binding using 
electrophoretic mobility shift assay and isothermal titration calorimetry.  
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CHAPTER 2       Materials and Methods 
2.1.  Materials 
 
Table 2.1. The manufacturer of the non-standard reagents and materials used in each 
experiment. All other reagents were of analytical grade. 
Method Material Manufacturer 
Mutagenesis, 
sequencing and 
transformation 
 
pET-lla plasmid GenScript, USA 
XL10 Gold ultra-competent cells New England Biolab, USA 
Site directed mutagenesis kit Strategene, USA 
Ampicillin Melford, UK 
T7 E. coli competent cells New England Biolab, USA 
GeneJet mini prep kit Thermo Fisher scientific, EU 
Primers for mutagenesis Iquaba biotech, RSA 
Sybr Gold nucleic acid gel stain Invitrogen, USA 
Expression Isopropyl βD-1-thiogalactopyranoside Melford, UK 
Lysozyme Sigma-aldrich, USA 
DNase Merck, Germany 
Phenylmethylsulfonyl fluoride Roche, Germany 
Purification and 
cleavage 
HisTrap column 
Benzamidine column 
GE healthcare, Sweden 
GE healthcare, Sweden 
Size exclusion 
chromatography 
Superdex 16/60 75 column 
Low range gel filtration calibration kit 
GE healthcare, Sweden 
GE healthcare, Sweden 
EMSA and ITC Duplex DNA Integrated DNA technologies- 
WhiteSci scientific, RSA 
Tricine SDS-
PAGE 
Page Ruler low range unstained protein ladder 100-3.4 
kDa 
Unstained protein molecular weight marker 116-14.4 
kDa  
Precision plus unstained protein ladder 
Thermo Fisher scientific, EU 
 
Thermo Fisher scientific, EU 
 
Bio-Rad, USA 
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2.2. Methods 
 
2.2.1. Mutagenesis, sequencing and transformation 
The codon optimised gene sequence of FOXP2 FHD (residues 504-594) were incorporated 
into the pET-11a vector (GenScript, USA). In addition to the FOXP2 gene, an N-terminal 
insert containing a six histidine tag (to aid in purification of the protein) and a thrombin 
cleavage site (in order to cleave the histidine tag) was incorporated. The pET-11a vector 
allows for selection with ampicillin and expression control via a T7 polymerase promotor 
(Fig. 2.1).  
 
Fig. 2.1. A: Schematic diagram of the pET-11a plasmid. The FHD gene sequence was inserted in 
between the T7 promotor and terminator indicated by the scissors B: The exact N-Terminal insert on the 
FOXP2 FHD. The histidine tag is displayed in purple; the thrombin cleavage site is displayed in green and 
the line shows where thrombin cleaves. 
 
XL10 gold ultra-competent cells were transformed with the pET-11a plasmid, containing 
the FOXP2 FHD insert. These cells were chosen as they are ultra-competent (the 
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transformation will likely work even if there is only a small portion of plasmid, which is 
likely when using a PCR product) and they contain a high copy number of plasmid. The 
transformation was performed by heat shock at 42 °C for 45 seconds. The transformed cells 
were cultured at 37 °C for 1 hour while shaking in super optimal broth with catabolite 
repression (SOC) media. SOC consists of 2% (w/v) tryptone, 0.5% (w/v) yeast, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2 and 20 mM glucose. The cells were subsequently grown 
overnight at 37 °C on agar plates containing 0.1 mg/ml of ampicillin for selection. Colonies 
were selected and were cultured in 2X YT media (1.6% (w/v) tryptone, 1% (w/v) yeast 
extract and 0.5% (w/v) NaCl) containing 0.1 mg/ml ampicillin at 37 °C for 16 hours with 
vigorous shaking. The culture was used to make up 1:1 glycerol stocks (cell culture: 80% 
glycerol) and a mini prep was done to extract the plasmid (GeneJet plasmid mini prep kit). 
The isolated plasmid was sent for sequencing (Inqaba Biotec, RSA) to ensure the gene 
sequence was correct. 
 
The WT isolated plasmid was subsequently used as a template for site-directed 
mutagenesis in order to generate the S557A and S557E mutants. Site-directed mutagenesis 
is a PCR reaction designed to produce specific point mutations in a plasmid. This is 
achieved by using long primers which encode the desired mutation meaning that in each 
cycle of PCR more mutant plasmids are produced. The WT template is digested using Dpn1 
after the PCR is finished resulting in a product containing only intact mutant plasmid 
(Papworth et al, 1996). Primers (Table 2.2) encoding each mutant were designed using 
PrimerX (http://www.bioinformatics.org). Complementary primers with the mutation in 
the centre were designed with melting temperatures between 75 and 85 °C and with a GC 
content between 40 and 60 %.  The primers were terminated with either a C or G. The 
primers were synthesised at Inqaba Biotec (RSA) and provided as a lyophilised pellet. The 
primers were resuspended in milli Q water at an appropriate concentration.  
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Table 2.2. Primers designed for mutagenesis using primer X. The CG content, melting 
temperature (TM), length and number of bases changed are displayed.  
  
Primer Sequence 
CG 
content 
(%) 
 
TM (°C) 
 
Length 
Number 
of base 
changes 
S557A 
Forward 
Primer 
5’ CGCGGTCCGTCATAATCTGGCTCTGCA 
CAAATGCTTCG 3’ 
 
55.26 
 
83.3 
 
38 
 
1 
S557A 
Reverse 
Primer 
 
5’ CGAAGCATTTGTGCAGAGCCAGATT 
ATGACGGACCGCG 3’ 
S557E 
Forward 
Primer 
 
5’ CGCGGTCCGTCATAATCTGGAACTGC 
ACAAATGCTTCGTGC 3’ 
 
53.66 
 
80.2 
 
41 
 
3 
S557E 
Reverse 
Primer 
5’ GCACGAAGCATTTGTGCAGTTCCAGA 
TTATGACGGACCGCG 3’ 
 
Mutagenesis was performed using the QuikChange site directed mutagenesis kit (Stratagene, 
USA) according to the manufacturer’s protocol. The components and cycling conditions used 
are displayed in Table 2.3 and Fig 2.2. The PCR products obtained were run on a 1% agarose 
gel and stained with Sybr Gold DNA stain (Invitrogen, Life technologies). The PCR products 
were used to transform XL10 gold ultracompetent cells, cultured and sequenced in the same 
manner as the WT. 
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Table 2.3. Setup of site- directed mutagenesis reactions.  
 
Reagent sample 
Reaction buffer (10x) 5 µl 
Ds DNA template (10-100 ng) 50 ng 
Forward primer 125 ng 
Reverse primer 125 ng 
dNTP mix 1 µl 
QuickSolution reagent 1.5 µl 
Milli Q water Volume made up to 50 μl 
PfuUltra HF DNA polymerase (2.5 U/µl) 1 μl 
 
 
Fig. 2.2. Schematic diagram indicating the PCR cycles used for all mutagenesis reactions. Methylated 
WT template plasmid (purple) was denatured. Primers (green), encoding the mutation, bound to denatured 
template. The rest of the plasmid was built from the primer by polymerase, which resulted in the synthetic 
strand containing the mutation (blue). These new plasmids (not methylated) containing the mutation also 
acted as templates in subsequent PCR cycles. After 18 cycles of PCR Dpn1 was used to digest methylated 
plasmid (initial WT template) leaving a non-methylated product which contained the mutation.  
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The sequenced WT and mutant plasmids were used to transform competent T7 E. coli cells using 
the same transformation protocol. Multiple colonies from each plate were selected and grown 
separately in 2X YT media at 37 °C for 16 hours with vigorous shaking. The cell culture was used 
to make glycerol stocks that were used for expression. 
 
2.2.2. Expression trials 
Expression trials were performed to determine the optimal expression conditions of the 
mutants. Glycerol stocks of the S557E and S557A mutants were used to inoculate separate 
100 ml flasks of 2X YT media containing 0.1 mg/ml of ampicillin. The cells were grown 
overnight at 37 °C with vigorous shaking. The cultures were used to inoculate flasks of 
100 ml 2X YT media and 0.1 mg/ml ampicillin at a 1 in 50 dilution. The flasks were 
incubated at 37 °C until an O.D 600 of 0.6 was reached. The flasks were cooled to 20 °C 
and isopropyl βD-1-thiogalactopyranoside (IPTG) (0 mM, 0.1 mM, 0.3 mM, 0.5 mM and 
0.7 mM) was added. The cultures were incubated at 20 °C and 1 ml samples were taken at 
various times (0 hours, 4 hours, 6 hours and 16 hours). The samples were centrifuged for 
5 minutes at 5000 xg and the supernatant was discarded. The pellet was resuspended in 100 
μl equilibration buffer (20 mM Tris, 30 mM imidazole and 500 mM NaCl, pH 7.5). The 
samples were sonicated to lyse the cells and were then centrifuged at 13 000 xg for 10 
minutes. The supernatant was separated from the pellet and the pellet was resuspended in 
equilibration buffer. Reducing sample buffer (12 % SDS, 30% glycerol, 0.05% Coomassie 
blue G-250 and 250 mM Tris/HCl at pH 7) was added to both the supernatant and the pellet. 
All samples were resolved on a 16 % tricine gel according to the protocol by Schägger, 
(2006). 
 
2.2.3. SDS-PAGE 
Tricine SDS-PAGE was performed per the protocol by Schägger, (2006). SDS-PAGE is a 
well-used technique in which molecules are separated through a gel matrix via an electric 
charge. The protein samples are denatured, reduced and exposed to SDS (Sodium dodecyl 
sulfate), a denaturing anionic surfactant, which binds the protein and not only gives it a 
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uniform charge but also forces it into a rod like shape. This ensures that the samples are 
fully denatured and are thus separated by size and not by charge or shape as they are drawn 
through a polyacrylamide matrix by an electric current. There are multiple methods of 
SDS-PAGE, however the glycine (Laemmli, 1970) and tricine (Schägger, 2006) are two of 
the most commonly used. These two methods differ in the buffering system (glycine-tris 
and tricine-tris) and subsequently the trailing ions. The pKa of the trailing ion effects its 
mobility and therefore the rate at which it in the gel. Tricine is ideal for separations of 
smaller proteins and peptides (Schägger & Gebhard, 1987). SDS-PAGE is a versatile 
technique which is frequently used to estimate sizes of proteins and observe if there are 
other protein contaminants in a sample. 
 
Samples of 50 μl were mixed with 16 μl of reducing sample buffer (12% (w/v) SDS, 6% 
(w/v) β-mercaptoethanol, 30% (w/v) glycerol, 0.005% Coomassie blue G-250 and 150 mM 
Tris-HCl, pH 7.5). Samples were subsequently boiled for 5 minutes and sonicated 3 times 
for 1 second to ensure the samples were fully denatured. The samples were vortexed and 
centrifuged to ensure the entire sample was mixed and all at the bottom of the tube. Samples 
(10 μl) were run on a 10% discontinuous gel consisting of acrylamide/bis-acrylamide stock 
(49.5% T and 3% C) and gel buffer (3 M Tris, 1 M HCl and 0.3% SDS at pH 8.45) cast 
and run using the BioRad mini protean electrophoresis system. The anode and cathode 
buffers were 1 M Tris at pH 8.9 (pH adjusted with HCl) and 1 M Tris, 1 M Tricine and 1% 
SDS at ̴ pH 8.25 (pH not adjusted). The gels were run at 45 V until the samples entered the 
separating gel at which point the voltage was increased to 160 V.  
 
2.2.4. Expression 
The wild type and both mutants were expressed in the same manner as previously described 
(Blane & Fanucchi, 2015). An overnight culture consisting of 50 ml 2X YT medium with 
0.1 mg/ml of ampicillin was inoculated with 1 ml of glycerol stock and was grown up 
overnight at 37 °C. Larger volumes of 2X YT media with 0.1 mg/ml ampicillin were 
inoculated with a 1 in 50 dilution of overnight culture. Cells were grown at 37 °C with 
shaking until an O.D 600 of 0.6 was reached. The cultures were then cooled to 20 °C before 
27 
 
0.5 mM IPTG was added. The cultures were incubated at 20 °C with shaking for 20 – 22 
hrs. The cells were pelleted by centrifugation at 5000 xg for 25 minutes at 4 °C and the 
medium was discarded. The pellet was resuspended in 50 ml of equilibration buffer per 
litre of culture and frozen at – 20 °C. Cells were thawed at 20 °C, 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 0.1 mg/ml of lysozyme was added. The lysate 
was then sonicated (power 18) X 5 for 30 seconds on ice. The lysate was left to incubate 
at 20 °C for 30 minutes after the addition of 0.01 mg/ml DNase 1 and 2 mM Mg Cl2. The 
lysate was centrifuged at 23 000 xg for 30 minutes at 4 °C to separate the soluble and 
insoluble fractions. The supernatant was used in the subsequent purification. 
    
2.2.5. Purification and Cleavage 
Immobilised metal affinity chromatography (IMAC) was the first purification step used. In 
this technique, the recombinantly expressed protein, with a histidine tag, specifically binds 
a column with either nickel or cobalt embedded. This is because the imidazole side chain 
of histidine has a high affinity to chelated metals. The rest of the cell lysate should not 
interact with the column as the His-tagged protein does and should there elute from the 
column. At this point multiple washing steps, such as salt or detergent, may be done to 
remove any DNA, proteins or lipids bound to the protein immobilised on the column. The 
pure protein is then eluted from the column with imidazole as imidazole competes with the 
His-tag to be the nickel or cobalt column (Arnau et al, 2006).    
 
A 5 ml (1.6 X 2.5 cm) HisTrap column (GE healthcare, USA) charged with Ni2+ was 
equilibrated with 10 column volumes of equilibration buffer (20 mM Tris, 500 mM NaCl 
and 30 mM imidazole, pH 7.5). The supernatant was loaded on to the column and the flow 
through was collected. After the flow through passed through the column, the column was 
allowed to re-equilibrate with equilibration buffer. Salt wash buffer (20 mM Tris, 1.5 M 
NaCl and 30 mM imidazole, pH 7.5) was used to wash the column for at least 5 column 
volumes to remove any DNA bound to the protein. After re-equilibration the His-tagged 
FHD was eluted using elution buffer (20 mM Tris pH 7.5, 500 mM NaCl and 500 mM 
imidazole). Fractions of the contamination peak and the main protein peak were collected. 
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Samples of the supernatant, pellet, flow through and all protein fractions were resolved on 
a 16 % tricine gel. 
 
As the His-tag made interfere with the function of the protein the His-tag was removed 
before subsequent studies. The His-tag is cleaved using thrombin as a thrombin cleavage 
site was incorporated into the recombinant protein (Fig 2.1). Once cleavage has occurred 
the thrombin, cleaved of His-tag and any protein with the His-tag still attached must be 
removed from the cleaved protein. The solution is applied to a benzamidine and IMAC 
columns connected in series. The thrombin binds to the benzamidine column while the His-
tag binds to the IMAC thus the cleaved protein elutes immediately (Young et al, 2012).  
 
Fractions containing the FHD were pooled and dialysed against thrombin cleavage buffer 
(20 mM Tris, 2 mM KCl and 100 mM NaCl, pH 8). Protein was centrifuged at 10 000 xg 
for 15 minutes to remove aggregates. Approximately 1 unit of thrombin was added per mg 
of protein and the solution was left to incubate at 20 °C for 3 to 4 hours. After addition of 
thrombin, a sample was taken every half an hour and analysed on a 16% tricine SDS-PAGE 
gel to test for cleavage. The solution was filtered through a 0.2 μM filter and was loaded 
on a pre-equilibrated 1 ml (0.7 X2.5 cm) benzamidine (GE healthcare, USA) and IMAC 
column connected in series. The cleaved FHD was collected in fractions as it flowed 
through the columns. Any uncleaved protein was eluted using elution buffer. Samples of 
all fractions collected were resolved on a 16 % tricine gel. 
 
2.2.6. Protein purity and concentration 
To ensure the protein was sufficiently pure, fractions of protein obtained from the 
purification were resolved on a 16% tricine gel and stained using Coomassie blue as 
described in section 2.2.3. Fractions containing the protein of interest without protein 
contamination were pooled and dialysed against a buffer of 10 mM HEPES, pH 7.5 and 
100 mM NaCl. The protein was then centrifuged at 10 000 xg for 10 minutes to remove 
any aggregates. An absorbance spectrum from 250 to 340 nm was obtained using a JASCO 
29 
 
V-630 spectrophotometer. The A280/A260 ratio was used to detect the presence of any 
nucleic acid contamination. 
 
The protein solution was centrifuged at 10 000 xg for 10 minutes and the buffer was the 
filtered through a 22 nM filter. In order to determine the concentration of the protein, the 
absorbance readings at 280, 340 and 260 nm were obtained for five dilutions of the protein. 
This was repeated in triplicate. The 340 nm reading was subtracted from the 280 nm 
reading to account for aggregation. The Beer-Lambert law (Eq. 1) was used to calculate 
the protein concentration. The theoretical extinction coefficient obtained from Expasy 
ProtParam (Gasteiger et al, 2005) used was 22460 M-1.cm-1. The extinction coefficient is 
calculated using equation 2 based of the primary structure using extinction coefficients for 
tyrosine, tryptophan and cysteine in water (Gill & von Hippel, 1989).  
 
 Eq 1.   𝐴 =  𝜀. 𝑐. 𝑙 
Where A is the absorbance at 280 nm (A.U), 𝜀 is the extinction coefficient of the FHD at 
280 nm (M-1.cm-1), c is the concentration of protein (M) and 𝑙 is the path length (cm). 
 
 Eq 2.  𝜀 (𝑝𝑟𝑜𝑡) = 𝑛(𝑇𝑦𝑟)×𝜀 (𝑇𝑦𝑟) + 𝑛(𝑇𝑟𝑝) × 𝜀 (𝑇𝑟𝑝) + 𝑛(𝐶𝑦𝑠)× 𝜀 (𝐶𝑦𝑠)  
Where n refers to the number of amino acid residues, 𝜀 is the molar extinction coefficient 
of the amino acid and 𝜀 (𝑝𝑟𝑜𝑡) refers to the predicted molar extinction coefficient of the 
protein. 
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2.2.7. Structural characterisation 
 
2.2.7.1. Size exclusion chromatography 
Gel filtration or size exclusion chromatography is a form of column chromatography where 
molecules are passed through a column containing a porous resin in order to separate them 
based on hydrodynamic volume/ Stokes radius. This technique was first described by 
(Ruthven et al, 1954). The Stokes radius is determined from a molecule’s molecular mass, 
shape and size. The smaller the molecule, or rather the smaller the hydrodynamic volume 
the more time the molecule spends in the pores. This means that molecules within the 
fractionation range of the column are separated based on hydrodynamic volume with larger 
molecules eluting first. There are now a variety of resins commonly used for size exclusion 
chromatography which include dextran (Sephadex/Sephacryl), agarose (Sepharose) and 
polyacrylamide polymers. Superdex resin is made up of a matrix consisting of agarose with 
covalently linked dextran chains. It is often used as it offers high resolution and is generally 
non-reactive with biological samples (Blurnenfeld & Gardner, 1985).  
 
Size exclusion chromatography was used to determine concentrations at which the WT, 
S557A and S557E FOXP2 FHDs were monomeric. A HiLoadTM 16/60 SuperdexTM 75 
prep grade column (GE healthcare, USA) was equilibrated with equilibration/ running 
buffer (10 mM Tris pH 7,5, 500 mM NaCl and 30 mM imidazole). Imidazole was included 
in the running buffer as it tends to help prevent the FOXP2 FHD from interacting with the 
column resin resulting in sharper peaks. One ml of protein at concentrations ranging 
between 25 and 200 μM of WT and mutant was loaded on to the column. Protein standards 
(GE healthcare low range gel filtration calibration kit) were run according to the 
manufacturer’s instructions in equilibration/ running buffer. The standards consisted of 
conalbumin (75 kDa), ovalbumin (44 kDa), carbonic anhydrase (29 kDa), ribonuclease A 
(13.7 kDa) and aprotinin (6.5 kDa). A standard curve was used to approximate the size of 
the WT and mutant FHDs. It was constructed by plotting the log Mw of each standard 
against the ratio of their respective elution volumes (Ve) and void volume (Vo). A linear 
31 
 
regression was fitted to the curve and the subsequent equation was used to calculate the 
sizes of the FHD and mutants based on their elution volumes.   
 
To determine dissociation constant of the WT FHD, four concentrations (25, 50, 100 and 
200 μM) were passed through the size exclusion column. The area under the monomer and 
dimer peaks were calculated using AKTA primeview 4 software. This was used to calculate 
the portion of protein in each peak. This was used to determine the protein concentration 
of each peak which was subsequently used to determine the Kd using equation 3 as 
described by Perumal et al, (2015). 
 
 Eq 3.  𝐾𝑑 = [𝑀𝑜𝑛𝑜𝑚𝑒𝑟]
2/[𝐷𝑖𝑚𝑒𝑟] 
where Kd refers to the dissociation constant and the monomer and dimer are given in μM. 
 
 
2.2.7.2.Far-UV circular dichroism 
Circular dichroism is a spectroscopic technique in which the differential absorption of right 
and left handed circularly polarised light by chiral molecules is measured. The average 
molar absorption coefficient (∆ε) is the difference between the left and right absorption 
coefficients. The spectra obtained in the far-UV range indicate the secondary structure of 
protein backbone. This is because of the chirality of the α-carbon displayed by all the amino 
acids with the exception of glycine (Greenfield, 2006). The shape of the far-UV spectrum 
(260 -190 nm) of a protein that is predominantly α- helical shows troughs at 220 and 218 
nm with a peak at 190 nm. Data at lower wavelengths is often noisy due to a lack of buffer 
transparency (Brahms & Brahms, 1980). Far-UV circular dichroism was used to probe 
significant secondary structural changes between the WT and mutant FHDs.  
 
The WT and mutant FHDs were dialysed into CD buffer (10 mM HEPES, pH 7.5 and 50 
mM NaSO4). The far-UV CD spectra of 10 μM samples were measured on a J-1500 CD 
spectrometer in triplicate. The spectra were measured from 250 to 180 nm. The scan speed 
was 100 nm/min and the bandwidth was 1 nm. Ten accumulations were taken. The spectra 
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were converted from θ (m.deg) to θMRE (deg.cm2.dmol-1) using equation 4 below where θ 
is the ellipticity and n is the number of peptide bonds. 
 
  Eq 4.   𝜃𝑀𝑅𝐸 =  
( 𝜃 (𝑚.𝑑𝑒𝑔).106)
(𝑙 (𝑚𝑚).  𝑐(µ𝑀).  𝑛)
 
Where θ refers to ellipticity (m.deg), 𝑙 refers to the path length (mm), c refers to 
the protein concentration (μM) and n refers to the number of peptide bonds. 
 
 
2.2.7.3. Intrinsic fluorescence 
Fluorescence spectroscopy makes use of the fluorescence phenomenon where a molecule 
(the fluorophore) absorbs a specific wavelength of light. This light excites electrons to a 
higher energy level and light is then emitted when the electrons move back to their ground 
state (Fig. 2.3). The emitted light is of a lower frequency/ longer wavelength than the light 
used to excite the fluorophore (Lakowicz, 2006). 
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Fig. 2.3. Jablonski diagram showing the fluorescence phenomenon. S0, S1 and S2 are energy levels and 
the lines indicate different vibrational energy levels. Light of a specific wavelength is used to excite 
electrons and the light is absorbed. Electrons fall back to the lowest vibrational energy level with energy 
loss due to heat and vibration (internal conversions). As the electron drops back down to the ground state 
the energy can either be emitted via light (fluorescence) or lost due to quenching (Lakowicz, 2006). 
 
Proteins may contain amino acids which act as fluorophores (tryptophan, tyrosine, 
phenylalanine and cysteine). Cysteine and phenylalanine exhibit extremely weak signals 
and are thus not used as intrinsic fluorophores. Tryptophan is most often used as it has a 
good signal and quenches the quantum yield of nearby tyrosine. Both tyrosine and 
tryptophan are excited at 280 nm and tryptophan can be exclusively excited at 295 nm. 
These intrinsic fluorophores can be used to probe tertiary structural changes in the protein 
around them. This is due to the sensitivity of the fluorophore to the polarity of its 
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environment which alters the emissions spectrum. A hyposochromic or blue shift indicates 
a decrease in the polarity which often indicates burying of the fluorophore within the 
protein and thus reducing its exposure to the polar solvent. A bathochromic or red shift 
indicates an increase in polarity which occurs when the fluorophore becomes more exposed 
to the polar solvent (Lakowicz, 2006).  
 
Intrinsic fluorescence of the WT, S557A and S557E mutant FHDs was used to determine 
if there are any tertiary structural changes in the FHD caused by mutating Ser557 to an 
alanine or glutamate. Fluorescence spectra of 2 μM protein in 10 mM HEPES, pH 7.5 and 
100 mM NaCl were determined in triplicate using a JASCO FP-6300 spectrofluorometer. 
Both 295 and 280 nm were used to excite the fluorophores (tryptophan at 295 nm and 
tryptophan and tyrosine at 280 nm) and the emission spectra were recorded from 280 to 
450 nm. The excitation and emission band widths were set at 5 and 2.5 nm respectively. 
The scanning speed was 500 nm/min and three accumulations were recorded.  
 
 
2.2.8. DNA binding studies 
The FOX family of proteins has a defined DNA consensus sequence which is 5’ 
[A/G][C/T][A/C]AA[C/T]A 3’ (Carlsson and Mahlapuu, 2002). The core binding 
sequence specifically for FOXP2 was defined as 5’ A[C/T]AAATA 3’ (Wang et al, 2003). 
More recently Nelson et al, (2013) found the sequence (5’-TGTTTAC-3’) to which 
FOXP2 binds with a high affinity. The FOXP2 2A07 crystal structure (Stroud et al, 2006) 
contains the Wang sequence 5’-AACTATGAAACAAATTTTCCT-3’. Cognate DNA 
containing the Nelson sequence binding site (5’-AGGTGTTTACTTTCATAG-3’) was 
used for this work. 
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2.2.8.1. Electrophoretic mobility shift assay 
Electrophoretic mobility shift assay (EMSA) is an electrophoresis based technique that is 
used to observed protein-DNA interactions. After allowing time for the protein to bind 
DNA, the solution is run on a 10% polyacrylamide gel. Protein-DNA complexes are larger 
than the free DNA and thus are retarded by the gel. This should result in the formation of 
two distinct bands visible on the gel after staining with a nucleic acid stain (Garner & 
Revzin, 1981). EMSAs, however, are often of low resolution because of the smearing of 
bands. These smears are a result of dissociation and re-association of the complex as the 
gel is run. The technique however is suitable to indicate if the complex associates and may 
give an indication of the dissociation constant for the binding interaction. 
 
The WT and mutant FHDs were dialysed against a buffer consisting of 10 mM HEPES, 
pH 7.5 and 100 mM NaCl. Reactions (50 μl) were set up containing increasing protein 
concentration from 0 to 20 μM (0 to 40X in excess of DNA), 0.5 μM DNA in EMSA 
binding buffer (10 mM HEPES, pH 7.5, 100 mM KCl, 1 mM EDTA, 1 mM MgCl2, 0.1 
mg/ml bovine serum albumin and 10 % (v/v) glycerol) and MilliQ water. The samples were 
left to incubate on ice for 1 hour. A 10% polyacrylamide gel was prepared with TBE buffer 
and was left to equilibrate to 4 °C along with running buffer (TBE buffer) for 1 hour. The 
gel was run at 4 °C for 1.5 hours immediately after loading the samples. The gel was stained 
with a 1:10 000 dilution of SYBR gold in TBE buffer for 5 minutes. The gels were 
visualised under UV light using the BioRad gel doc system. 
 
2.2.8.2. Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) is based on measuring the heat absorbed or released 
as one of the reactants is titrated into the other. The isotherm obtained can be used to 
determine thermodynamic properties such as the binding affinity (Ka), enthalpy, entropy 
and free energy. The Ka and enthalpy (ΔH) can be derived directly from the titration. This 
can be used to calculate the Gibbs free energy (ΔG) and entropy (ΔS) (Ladbury & 
Chowdhry, 1996) using equations 5 and 6. 
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  Eq 5.   𝛥𝐺 = 𝑅𝑇𝑙𝑛 (𝐾𝑎) 
Where 𝛥𝐺 refers to Gibbs free energy (kJ/mol), R refers to the gas constant, T 
refers to temperature (K) and Ka refers to the dissociation constant. 
 
  Eq 6.  𝛥𝐺 =  𝛥𝐻 − 𝑇𝛥𝑆 
Where 𝛥𝐺 refers to Gibbs free energy (kJ/mol), 𝛥𝐻 refers to the enthalpy (kJ/mol), 
T refers to the temperature (K) and 𝛥𝑆( refers to the entropy (kJ/mol). 
 
ITC was used to study binding interactions between WT and mutant proteins and DNA. 
Titrations were done on a Nano isothermal titration calorimeter (TA instruments, USA) as 
previously described (Morris & Fanucchi, 2016). The WT, S557A, S557E FHDs and DNA 
were dialysed against 10 mM HEPES, pH 7.5 and 100 mM NaCl. A sample of the buffer 
was then filtered through a 0.2 μM filter to remove any particles. The protein and DNA 
samples were centrifuged at 10 000 xg for 10 minutes. The protein (100 μM) was loaded 
into the sample syringe and DNA (5 μM) was loaded into the sample cell. The 
concentration of DNA was determined using the same method as the protein using the 
experimental extinction coefficient of 256 016 M-1·cm-1 (Kibbe, 2007). The ITC was 
allowed to equilibrate while stirring at 250 rmp. Once equilibrated, the titration was started. 
Injection volumes of 5 μl were used. Approximately 40 injections were done.  
 
2.2.9. Molecular Docking 
Molecular docking was done in an attempt to computationally observe differences in 
binding between the WT and mutants in order to elucidate reasons for the differences. 
Nelson DNA was modelled using the build nucleic acid function in Accelrys Discovery 
studio 4.1. The monomeric FHD structure was obtained from chain K of the 2A07 crystal 
structure (Stroud et al, 2006). Serine 557 was mutated to either an alanine or a glutamate 
using Chimera 1.7 (Pettersen et al, 2004). A model containing phosphorylated serine 557 
was made in the PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC using 
the PyTMs plugin. The DNA and protein models were energy minimised using Chimera 
1.7 (Pettersen et al, 2004). All the protein models were docked to the DNA model using 
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the easy interface HADDOCK (Dominguez et al, 2003). High ambiguity driven docking 
approach (HADDOCK) makes use of ambiguous interaction restraints (AIRS) which is 
biochemical/biophysical information to aid in docking. The docked structures are 
subsequently ranked based on their intermolecular energy which considers electrostatic and 
Van der Waals energy along with the AIRs. The AIRs in the easy interface which was used 
were automatically generated based on user defined active residues (residues involved 
directly in the interaction) and passive residues (the surface residues around the binding 
site). Two residues were defined as active residues in the protein (Arg553 and Asn550). 
Arg553 was used because when it is mutated, DNA binding is abolished (Vernes et al, 
2006) and thus makes an important DNA contact. Asn550 was chosen as it is central in 
helix 3 and makes hydrogen bonds to the DNA backbone in the crystal structure. His554, 
Lys549, Arg553 and His559 were defined as passive residues as they are the surface 
exposed residues of helix 3 surrounding Arg553 and Asn550 (Dominguez et al, 2003). The 
docked models were grouped into clusters based on their similarity. The best scored 
structure of the cluster with the protein bound to the binding site was analysed. 
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CHAPTER 3         Results 
 
The effect of phosphorylation of Ser557 in the FOXP2 FHD on structure and DNA binding is 
unknown. In order to determine the effect of phosphorylation of serine 557 may have, serine 557 
was mutated to both a glutamate to act as a phosphomimic, and an alanine to act as a control. 
Structural characterisations (size exclusion chromatography, far-UV circular dichroism and 
intrinsic tryptophan fluorescence) and DNA binding studies (EMSA, ITC and molecular docking) 
were conducted with the WT FOXP2 FHD and, S557A and S557E mutants to observe any changes 
caused by phosphorylation of serine 557. 
 
3.1. Mutagenesis and sequencing 
 
Primers for mutagenesis (Table 2.2) were designed using primer X. The pET-11a plasmid 
incorporated with the WT FOXP2 FHD gene was used as a template for mutagenesis. The 
PCR products obtained from the mutagenesis reactions were resolved on a 1 % agarose gel 
(Fig. 3.1). A large band was present in each lane which is likely the intact mutant plasmids. 
The digested plasmid is present as a band at the bottom of the gel and as a feint smear along 
the lanes. The PCR products were used to transform T7 E. coli cells. The cells were grown up 
and the plasmids were extracted using a mini prep kit. The extracted plasmids were sequenced 
and the correct mutations were found to have occurred (Fig. 3.2.).  
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Fig. 3.1. PCR product of S557A and S557E site- directed mutagenesis. PCR product obtained from 
PCR reaction resolved on a 1% agarose gel stained with SYBR gold nucleic acid stain. The intact 
plasmid is visible as a clear band at the top of the gel. Lane 1 contains the O’GeneRuler 1 kb DNA 
Ladder (Thermo fisher scientific, EU). 
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Fig. 3.2. Sequencing results of S557A (A) and S557E (B) mutant plasmids and alignment with 
the WT FOXP2 FHD plasmid (C and D). The green and blue blocks in A and B indicate the 
alanine and glutamate codons respectively. The arrows above indicate nucleotides which were 
changed. The DNA sequencing of the mutant plasmids (Query) were translated to protein using 
Expasy translate (Gasteiger et al, 2005) and aligned with the WT protein (Sbjct) sequence using 
NCBI Blast (blast.ncbi.nlm.nih.gov). The correct mutation has occurred in the S557A (C) and 
S557E (D) plasmids. 
 
3.2. Expression trials 
Expression trials were performed to determine the optimal expression conditions of the 
mutant FHDs only, as expression conditions for the WT have been previously determined 
(Blane & Fanucchi, 2015). The conditions chosen were based on the optimal expression 
conditions for the WT. Expression trials were conducted at 20 °C with varying concentrations 
A B 
C 
D 
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of Isopropyl βD-1-thiogalactopyranoside (IPTG) to determine the best conditions to express 
the S557A and S557E FHDs. In figure 3.3 the 16% tricine SDS-PAGE gels of the S557A 
expression trial are shown. The best soluble expression conditions appear to be with 0.5 mM 
IPTG for 22 hours at 20 °C.   
  
 
 Fig. 3.3. S557A expression trials (2, 4, 6 and 22 hours). The number in bold indicates the IPTG 
concentration in mM. S and P stand for supernatant and pellet respectively. The arrow indicates the 
expected position of the FHD band ( ̴14 kDa). The best apparent expression conditions appear to 
be using 0.5 mM IPTG and incubating at 20 °C for 22 hours (green block). The sizes of the bands 
in the Thermo scientific unstained protein molecular weight marker (166-14.4 kDa) are indicated 
on each band in kDa. 
 
In figure 3.4 the 16% tricine SDS-PAGE gels of the S557E expression trial is shown. The best 
soluble expression conditions appear to be with 0.5 mM IPTG for 22 hours at 20 °C.   
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Fig. 3.4. S557E expression trials (2, 4, 6 and 22 hours). The number in bold indicates the IPTG 
concentration in mM. S and P stand for supernatant and pellet respectively. The arrows indicate the 
expected position of the FHD band (1̴4 kDa). The best apparent expression conditions appear to be 
using 0.5 mM IPTG and incubating at 20 °C for 22 hours (blue box). The sizes of the bands in the 
Thermo scientific unstained protein molecular weight marker (166-14.4 kDa) are indicated on each 
band in kDa. 
 
3.3. Expression and purification 
In order to obtain sufficient quantities of the WT, S557E and S557A FOXP2 FHDs to perform 
structural characterisations and binding studies, the FHDs were expressed using the pET-11a 
expression vector in T7 E.coli cells. The proteins were subsequently purified using IMAC and 
the His-tag was subsequently cleaved. The following sections show an example of how the 
WT FOXP2 FHD was purified (the S557A and S557E mutants were purified the same way). 
 
3.3.1. Immobilised metal affinity chromatography 
The WT FOXP2 FHD was expressed for 22 hours at 20 °C after induction with 0.5 mM IPTG. 
The soluble fraction of the cell lysate was loaded on to the IMAC column and fractions were 
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collected of the eluted protein (F1-F3 in Fig. 3.5.B). Fractions 2 and 3 in Fig 3.5B contained 
large quantities of FOXP2 FHD and were thus pooled and the His-tag was cleaved using 
thrombin. There were still large quantities of contaminants in the pooled fractions but these 
containments aggregated during dialyses against thrombin cleavage buffer and were removed 
by centrifugation at 10 000 xg for 10 minutes. 
 
Fig 3.5. Immobilised metal affinity chromatography (IMAC) of the WT FOXP2 FHD. A: The 
IMAC elution profile of the WT FHD. The blue line is the absorbance (mAu) and the red line is 
the conductance (mS/cm). The protein was eluted using imidazole as indicated by the peak at 250 
ml. B: 16% tricine SDS page gel of samples collected from the purification. S- supernatant. P-
Pellet. FT-flow through from the IMAC column. F1-3- fractions collected of the eluted WT FHD 
peak. The Thermo scientific low range unstained protein ladder (100-3.4 kDa) was used. 
 
3.3.2. His-tag cleavage 
Thrombin was added to the dialysed protein and a sample was taken every half an hour and 
resolved on an 16% tricine SDS-PAGE gel. In order to remove the cleaved off His-tag and 
thrombin the protein solution was passed through a benzamidine column (to bind the 
thrombin) and an IMAC column (to bind the His-tag). In Fig 3.6.B it can been seen that 
after 3 hours there is still some uncleaved protein. F1 and F2 are the samples of the fractions 
of the cleaved protein eluted from the IMAC and benzamidine columns. The protein was 
free from protein contaminants and could be used for further study. 
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Fig 3.6. WT FOXP2 His-tag cleavage. A: The elution profile of cleaved protein from the IMAC 
and benzamidine column. The first peak contains the cleaved FHD which passes through both the 
IMAC and benzamidine columns. The second peak contains uncleaved FHD which bound the 
IMAC column and was eluted using imidazole. B: 16% tricine SDS-PAGE gel showing samples 
taken at time intervals during cleavage and samples of the cleaved protein eluted from the IMAC 
and benzamidine columns (F1 and F2). The uncleaved (UC) and cleaved (C) proteins are indicated 
on the gel. The Thermo scientific low range unstained protein ladder (100-3.4 kDa) was used. 
 
3.3.3. Confirmation of purity of the WT, S557A and S557E FOXP2 FHDs 
Samples of the purified WT, S557A and S557E FOXP2 FHDs were resolved on a 16% 
tricine SDS-PAGE gel and the size was approximated using a molecular weight marker 
(Fig 3.7). In each gel (WT, S557A and S557E) there is only 1 band present indicating the 
protein is free from protein contamination. The size of the WT, S557A and S557E proteins 
were calculated to be 9.9, 10 and 10.1 kDa respectively which are all close to the predicted 
size, determined by Expasy ProtParam (Gasteiger et al, 2005), of the FHD which is 10.1 
kDa. 
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Fig 3.7. 16% tricine SDS-PAGE of the purified and cleaved WT, S557A and S557E FHDs and 
their calculated sizes. A sample of the purified WT(A), S557A(B) and S557E(C) alongside the 
molecular weight marker. The standard curve was used to calculate the size of the protein. The 
calculated sizes of the WT, S557A and S557E were 9.9, 10 and 10.1 kDa respectively. The 
molecular weight of each standard in the marker is indicated on the gel and on each point in the 
graph. 
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3.4. Protein purity and concentration 
The concentration of the WT, S557E and S557A FOXP2 FHD was determined using a dilution 
series and the Beer-Lambert law (E.q. 1). An absorbance spectrum of each protein was 
obtained using a JASCO V-630 spectrophotometer (Fig 3.8). The peaks at 280 nm and 295 
nm indicate the absorbance of tyrosine and tryptophan residues. No peak is observed at 340 
nm which indicates that there is not a significant amount of aggregation. The A280/A260 ratio 
is 1.7 for all the proteins which indicates that the samples are free of DNA contamination. 
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Fig 3.8. Absorbance spectra of the WT (purple), S557A (green) and S557E (blue) FOXP2 
FHD. Spectra were taken on a JASCO V-630 spectrophotometer from 250 to 240 nm. All spectra 
peak at 280 nm, indicative of a protein sample and the A280:A260 ratio is 1.7 implying negligible 
DNA contamination.  
3.5. Structural characterisations 
Structural characterisations were performed on the WT, S557A and S557E FHD in order to 
see if there are any structural changes in the mutants in comparison to the WT. The structural 
characterisations performed included size exclusion chromatography (quaternary structure), 
Far-UV circular dichroism (secondary structure) and intrinsic tryptophan fluorescence 
(tertiary structure). 
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3.5.1. Size exclusion chromatography 
Size exclusion chromatography was used to observe the quaternary structure of the protein in 
solution. The column used was a HiLoadTM 16/60 SuperdexTM 75 prep grade column (GE 
healthcare, Sweden). The elution and sample buffer consisted of 10 mM Tris pH 7.5, 500 mM 
NaCl and 30 mM imidazole.  
 
Blue dextran (Fig. 3.9. A) was loaded first, separately from the rest of the standards as it may 
interact and cause incorrect sizing (Marshall, 1970). Blue dextran is larger than the 
fractionation range of the column and thus elutes at the column void volume. The blue dextran 
peak was sharp and symmetrical with exception of a small amount of tailing which indicated 
that the column was in good condition (Hong et al, 2012). The GE healthcare standards (Fig 
3.9. B) resolved well and all peaks were sharp and symmetrical. The log Mw of each standard 
was plotted against the ratio of their respective elution volume (Ve) and the void volume (Vo). 
A linear regression was fitted and the equation was used to size the protein on subsequent runs. 
The R2 was 0.9976 and the equation was y = -1.4479x + 3.5689. 
 
 
Fig. 3.9. A: Size exclusion elution profile of GE Healthcare gel filtration standards. The blue 
dextran (Blue) eluted at 48.3 ml which indicates the void volume. The GE healthcare standards 
consisted of conalbumin (75 kDa), ovalbumin (44 kDa), carbonic anhydrase (29 kDa), ribonuclease 
A (13.7 kDa) and aprotinin (6.5 kDa). B: Standard curve of the gel filtration standards. A 
standard curve was constructed by plotting Ve/Vo vs the Log Mw. The R2 was 0.9976 and the 
equation was y = -1.4479x + 3.5689. 
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The WT, S557A and S557E mutants were loaded on the HiLoadTM 16/60 SuperdexTM 75 
prep grade column under the same conditions as the standards. Concentrations of 50 and        
100 μM were chosen to see if the mutants resulted in a change in the monomer-dimer ratio 
(Fig. 3.10). The monomeric FHD is 10.2 kDa (Gasteiger et al, 2005) and elutes at  ̴ 84 ml. 
Using the standard curve (Fig. 3.9), the calculated size of the monomeric FHD is 11.2 kDa. No 
dimer was observed for the S557A or S557E mutants but a small portion of dimer was observed 
for the WT at 100 μM. The dimer peak eluted at 76 ml. The calculated size of the dimer using 
the standard curve (Fig. 3.9) was 19.5 kDa.  
 
Fig. 3.10. Size exclusion chromatography profiles of the WT (purple), S557A (green) and 
S557E (blue) FHDs at 50 and 100 μM.  The buffer used consisted of 20 mM Tris pH 7.5, 500 
mM NaCl and 30 mM Imidazole. The column was a a HiLoadTM 16/60 SuperdexTM 75 prep 
grade column. 
 
Because some dimer was observed for the WT at 100 μM, a range of WT protein concentrations 
was passed through the size exclusion column to calculate the Kd of dimerisation (Fig 3.11). 
This was found to be 896 μM using equation 3.  
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Fig. 3.11. A: Size exclusion chromatography of the WT FHD at varying concentrations (25 to 
200 μM). B: WT Kd of dimerisation curve. The Kd of dimerisation of the WT FHD was calculated 
using the equation Kd = [Monomer]2/[Dimer]. The Kd was calculated as 896 μM using the regression 
curve (Y = 896.35x + 195.25). The R2 value of the curve was 0.9934. 
 
3.5.2. Far-UV circular dichroism 
Far-UV circular dichroism was done to observe the effect of the mutation on the overall 
secondary structure of the FHD. According to the crystal structure (2A07), the WT FOXP2 
FHD bound to DNA (Stroud et al, 2006) is predominantly helical. A predominately alpha 
helical protein will display troughs at 222 and 208 nm and a peak at 190 nm on a far-UV 
circular dichroism spectrum (Kelly et al, 2005). In figure 3.12A the WT, S557A and S557E 
FHDs in the presence and absence of DNA all display the characteristic signal of an alpha 
helical protein. Furthermore, it can be seen in Fig 3.12C that the spectra are very similar and 
overlay quite well. The difference in the signal obtained for S557A is not significantly 
different. DNA does appear to affect the secondary structure of the WT and both mutants. In 
Fig 3.12A and B it is apparent that DNA acts by decreasing the helical content. Figure 3.12D 
and E are plots of the difference in mean residue ellipticity, at 222 and 208 nm, between the 
protein alone and the protein in the presence of DNA. There is no change in the difference in 
mean residue ellipticity at 222 nm or 208 nm between the WT and S557A. The S557E FHD 
however displays a greater difference between the θMRE222 of the protein and the protein in 
the presence of DNA. This indicates that the DNA reduces the alpha helical content of the 
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S557E protein more than it does the WT and S557A protein. The difference however is small 
and may not be significant. 
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Fig. 3.12. Far-UV circular dichroism of the WT, S557A and S557E FHDs. A: Averaged Far-
UV CD spectra of the S557A (green), S557E (blue) and WT (purple) FHD in the presence and 
absence of DNA. B:  Averaged Far-UV CD spectra of the S557A (green), S557E (blue) and WT 
(purple) FHD in the presence of DNA. C: Averaged Far-UV CD spectra of the S557A, S557E and 
WT FHD in the absence of DNA. D: The difference in θMRE222 between the protein alone and in 
the presence of DNA. E: The difference in θMRE208 between the protein alone and in the presence 
of DNA.F: The WT FOXP2 FHD (2A07) coloured by secondary structure. Helices (blue) make up 
most of the structure. There is a beta-sheet shown in purple and some random coils in green. 
208 nm 
222 nm 
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3.5.3. Intrinsic fluorescence 
Intrinsic tryptophan fluorescence was done to observe if there is a change in overall tertiary 
structure between the WT and Ser557 mutants. The Fluorescence spectra were recorded with 
excitation wavelengths at both 280 and 295 nm in the presence and absence of DNA (Fig 3.13). 
In Figure 3.13A and B there are two peaks visible for all the FHDs, in the absence of DNA, at 
the same maximum emissions (330 and 336 nm). There are no wavelength shifts in the spectra 
of any of the proteins in the absence of DNA at both 280 and 295 nm. The lower fluorescence 
intensity observed for the WT is within error and is negligible. In the presence of DNA there 
was no wavelength shifts of the peaks in the WT, S557A or S557E FHDs (Fig 3.13C and D). 
The protein fluorescence is quenched by the DNA. The most quenching is observed for the 
WT followed by the S557A and S557E FHDs which can be seen in Fig3.13E and F.  
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Fig 3.13. Intrinsic tryptophan fluorescence of the WT, S557E and S557A FHDs. A: Intrinsic 
fluorescence spectra of the WT (purple), S557A (green) and S557E (blue) with excitation wavelengths 
of 280 nm. B: Intrinsic fluorescence spectra of the WT (purple), S557A (green) and S557E (blue) with 
excitation wavelengths of 295 nm. C: Intrinsic fluorescence spectra of the WT (purple), S557A (green) 
and S557E (blue) in the presence of DNA with excitation wavelengths of 280 nm. D: Intrinsic 
fluorescence spectra of the WT (purple), S557A (green) and S557E (blue) in the presence of DNA with 
excitation wavelengths of 295 nm. E: The difference in fluorescence intensity (excitation 280 nm and 
330 nm peak) between the WT, S557E and S557A in the absence and presence of DNA. F: The 
difference in fluorescence intensity (excitation 280 nm and 336 nm peak) between the WT, S557E and 
S557A in the absence and presence of DNA. Fluorescence spectra were recorded with a JASCO FP-
6300 spectrofluorometer.  
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3.6. DNA binding studies 
 
3.6.1. Electrophoretic mobility shift assay 
Electrophoretic mobility shift assays (EMSA) are a good qualitative tool to observe if there is 
formation of a complex. EMSAs were done to see if the WT, S557A and S557E proteins are 
capable of binding DNA. In Fig.3.14 EMSAs of the WT, S557E and S557A FHDs are 
displayed. Binding for the WT was evident at 3:1 protein to DNA ratio (purple block). The 
S557E and S557A mutants displayed slight smears at 1:40 and 1:20 protein to DNA 
respectively, indicating very weak binding. Since there are bands present on the S557A and 
S557E FHDs EMSA, it shows that they can bind DNA and are correctly folded.  
 
Fig. 3.14. Electrophoretic mobility shift assay of the WT (purple), S557E (blue) and S557A 
(green).  The band present at the bottom of each gel and in each well, is the free DNA band. The 
band present higher up the gels (smeared) is the protein-DNA complex.  
 
3.6.2. Isothermal titration calorimetry 
Isothermal titration calorimetry was done to obtain quantitative binding parameters of the FHD 
binding to DNA. S557A and S557E mutants did not display any binding under the same 
conditions used for the WT (Fig. 3.15). The parameters obtained from fitting the WT ITC 
(Table 3.1) are similar to values obtained from previous work (Morris & Fanucchi, 2016). The 
WT FHD binds to Nelson DNA with a large enthalpic term (-27.14 kJ/mol). The entropic term 
is also favourable (TΔS is 10.96 kJ/mol/K). The ΔG is -38.1 kJ/mol and the Kd was found to 
be 0.1628 μM. The stoichiometry of 1.423 however was unexpected. This could be a result of 
a monomer: dimer mixture where the dimer could possibly bind two strands of DNA or there 
may be an additional binding site on the DNA. 
WT S557E S557A 
1:3 1:40 1:20 
Free DNA 
DNA 
protein 
complex 
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Fig. 3.15. ITC titrations of the WT, S557A and S557E FHD into Nelson DNA. The isotherms 
were generated by titrating multiple small volumes of protein (90-120 μM) into DNA (8- 10 μM). 
Only the WT shows binding with a Kd of 162.8 nM. 
 
 
 
 
 
 
 
 
 
 
 
S557A S557E 
WT 
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Table 3.1 Thermodynamic parameters obtained from titrating WT into Nelson DNA. 
Variable Value Error 
Kd (μM) 0.1628 ±0.062 
n 1.423 ±0.04 
ΔH (kJ/mol) -27.14 ±1.282 
ΔG (kJ/mol) -38.1 
 
TΔS (kJ/mol/K) 10.96 
 
   
3.6.3. Molecular docking 
Modelled Nelson DNA was docked to the structure of the WT, phosphorylated WT (Phos-WT) 
and the Ser557 mutants using HADDOCK. The S557A and S557E protein models were made 
by mutating Ser557 to alanine and glutamate respectively using Chimera 1.7 (Pettersen et al, 
2004). The Phos-WT model was made by phosphorylating the WT crystal structure using 
PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC with the PyTMs plugin. 
Docking to DNA was done with HADDOCK. HADDOCK scores the models using a score 
comprised of the electrostatic energy, van der Waals energy, desolvation energy and restraints 
violation energies (Kastritis & Bonvin, 2010). The HADDOCK scores however are not 
comparable between different complexes. In general docking scores are not correlated to 
binding affinity and their purpose is the comparison of different docked models of the same 
structure (Kastritis & Bonvin, 2010). For this reason Chimera 1.7 (Pettersen et al, 2004) was 
used to analyse binding of each model by looking at the number of hydrogen bonds formed, 
the number of contacts and the surface area buried upon binding (Fig 3.16).   
The WT has 6 potential hydrogen bonds whereas the Phos-WT, S557A and S557E models 
have 2, 4 and 4 respectively (Table 3.2, Fig. 3.17). The WT in addition to having the most 
hydrogen bonds also has the greatest buried surface area upon DNA binding and forms the 
most contacts. The S557A mutant model has fewer hydrogen bonds than the WT but exhibits 
similar buried surface area upon DNA binding and number of contacts. The S557E mutant and 
phosphorylated WT models display the fewest contacts and the smallest buried surface area 
upon binding. This suggests that the WT and S557A FHDs may have the greatest number of 
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interactions with the DNA and likely greater binding affinities than the S557E mutant and 
Phos-WT. 
 
Fig. 3.16. Number of hydrogen bonds (A), buried surface area upon DNA binding (B) and 
number of contacts (C) of the docked WT, S557A, S557E and Phos-WT models. The models 
were docked using HADDOCK to a model of Nelson DNA. The number of hydrogen bonds, buried 
surface area and number of contacts was determined using Chimera 1.7 (Pettersen et al, 2004).  
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Table 3.2: Hydrogen bonds formed between protein residues and nucleotides in the 
docked models of the WT, phosphorylated WT, S557A and S557E. 
  Residue Nucleotide 
WT 
Asn550 Thy29 
Arg553 Thy30 ** 
Asn555 Ade12, Ade13 
Tyr509 Ade13 
Phos-WT 
Asn555 Ade13 
Tyr509 Ade 13 
S557A 
Arg553 
Tyr509 
Thy30 *** 
Ade12 
S557E 
Arg 553 Thy30 ** 
Asn550 
Tyr509 
Ade13 
Ade13 
The shaded nucleotide indicates at hydrogen bond formed between a specific DNA base 
rather than a backbone interaction. * represent interactions where multiple hydrogen bonds 
may be shared among the same residue and nucleotide.  
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Fig. 3.17. WT (A), Phos-WT (B), S557A (C) and S557E (D) docked to Nelson DNA using HADDOCK. 
The protein models were modified from the 2A07 crystal structure (Stroud et al, 2006) and the DNA models 
were made in the Acceryls discovery suite 4. The hydrogen bonds between the protein and DNA in each 
model are displayed with blue dashes. The residues involved in hydrogen bonding are labelled. 
 
A structural alignment of the Phos-WT, S557A and S557E docked models to the WT docked 
model was done using PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC (Fig 
3.18). The RMSD values for the alignment of the WT to Phos-WT, S557A and S557E were 0.495, 
0.339 and 0.371 respectively. It is apparent that the proteins align well with the biggest differences 
occurring in the random coil regions. The major difference between the models is the DNA.  This 
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suggests that the phosphomimetic, and phosphorylation, does not significantly alter the structure 
of the protein but rather the interactions and position of the DNA when binding occurs. It is 
apparent from the alignment that the phosphorylated model is not bound as deeply in the major 
groove of the DNA as the WT model. This could account for the decreased binding affinity 
observed with the EMSA and ITC experiments. 
 
Fig. 3.18. Structural alignment of the docked models of the WT (purple), Phos-WT (orange), 
S557A (green) and S557E (blue). The Phos-WT, S557A and S557E complexes were aligned to 
the WT structure and the RMSD values were 0.495, 0.339 and 0.371 respectively. Alignment was 
done using the Schrodinger PyMol molecular graphics system. 
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CHAPTER 4         Discussion 
 
The aim of the study was to establish the possible effects of phosphorylation of Ser557 on the 
structure and DNA binding of the FOXP2 FHD. A phosphate group adds considerable charge and 
bulk to a residue. This has been known to cause conformational, structural and electrostatic 
changes to proteins (Johnson & Barford, 1993). In some cases, this PTM changes the function of 
a protein and even acts as an “on” or “off” switch. In FOXO1, phosphorylation of the equivalent 
serine (Ser218) inhibits DNA binding (Brent et al, 2008). To observe if this is the case for Ser557 
in FOXP2, a glutamate mutant was made so as to mimic phosphorylation. An alanine mutant was 
also made to act as a control to ensure changes observed were not due to disruption of the structure 
of the protein. Since Ser557 is located at the C-terminal end of helix 3 in the FOXP2 FHD, it is 
likely that the addition of a phosphate group (bulky and negatively charged) will electrostatically 
and sterically inhibit DNA binding. If phosphorylation of Ser557 does inhibit DNA binding of 
FOXP2, phosphorylation may be a mechanism by which FOXP2 is regulated in vivo.  
As phosphorylation can induce structural changes in proteins (Johnson & Barford, 1993), Far-UV 
circular dichroism and intrinsic tryptophan fluorescence were performed to establish if the S557E 
mutation causes secondary and tertiary structural changes. The Far-UV CD spectra (Fig 3.14C) of 
the S557E and S557A mutants overlay well the WT which indicates that the secondary structure 
of the FHDs is the same. This implies that the secondary structure of the FHD is not altered by 
mutation of serine 557 or the phosphomimetic. In addition to this, the shape of the spectra indicates 
that the proteins are predominantly alpha helical which corresponds with the crystal structure 
(2A07) which gives evidence that the WT, S557A and S557E FHDs are correctly folded.  
The intrinsic tryptophan fluorescence spectra of the WT, S557A and S557E (excitation at 295 nm 
and 280 nm) have an emission maximum at 330 nm with a shoulder at 336 nm (Fig 3.13). The 
FHD contains three tryptophan residues so the presence of the shoulder implies that one of the 
tryptophans is in a different polar environment to the others thus has a shifted emission.  The 
spectra of the mutants do not overlay with the WT; however, the lack of wavelength shifts indicates 
that the fluorophores are in the same environment as they are in the WT. Amino acids with charged 
side chains, electron acceptors (protonated carboxyl groups), disulfides and amines have been 
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shown to quench fluorescence (White, 1958; Christov et al, 2004; Lakowicz, 2006). However, the 
decrease in fluorescence intensity of the WT is unlikely to be due to quenching as the ratio between 
the peak and the shoulder is the same in the WT (1.01) and mutants (1.01). The decrease in 
fluorescence intensity, in the WT, is therefore likely to be caused by a slight difference in 
concentration of the protein rather than a tertiary structural change. The conserved secondary and 
tertiary structure in the glutamate mutants shows that if there is a change in the protein’s DNA 
binding upon phosphorylation of Ser557 it is unlikely to be due to conformational changes but 
more likely to be due to electrostatic or steric interference.  
Size exclusion chromatography was used to establish at what concentrations the WT, S557A and 
S557E FHDs were monomeric and assess any changes that phosphorylation of Ser557 may have 
on the quaternary structure of the FHD. Both serine 557 mutants exhibited a decreased propensity 
to dimerise at concentrations at which the WT FHD showed a small portion of dimer (Fig 3.10). 
This indicates that Ser557 does play a role in dimerisation of FOXP2, and the mutation of Ser557 
inhibits dimerisation since both the serine mutants (S557A and S557E) do not dimerise at 
concentrations below 100 μM. When the FOXP2 FHD forms a domain swapped dimer, helix 2 is 
extended as the turn between helix 2 and helix 3 opens (Fig 1.6). The domain interface consists of 
multiple hydrophobic residues with charged and polar residues facing away from the interface 
(Stroud et al, 2006). According to the crystal structure (2A07) Ser557, located on the C-terminal 
end of helix 3, does not appear to play any role in the dimer interface or be involved in DNA 
binding in the dimeric form. The mutation and phosphorylation of Ser557 may affect the formation 
of the dimer by preventing the reshuffling of the domains or even stabilisation of the helix in the 
domain swapped form. Interestingly, although not much is known about DNA binding of the 
dimeric form of the FOXP2 FHD, it has been postulated that the dimeric form of the FHD may 
bind DNA at a higher affinity than the monomer (Morris & Fanucchi, 2016). Furthermore, the 
presence of DNA may induce dimerisation of the FHD and that the purpose of dimerisation may 
be chromosomal looping or DNA bending (Stroud et al, 2006).  
 
An electrophoretic mobility shift assay was initially used to probe if the mutant protein could bind 
DNA and give an indication of the Kd in relation to the WT. The EMSAs showed that the S557E 
and S557A mutants could bind DNA however the Kd appeared to be significantly lower than that 
of the WT. The quality of the S557A and S557E EMSAs did not match up to that of the WT as the 
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protein- DNA complex could not be distinguished. The smearing of bands in EMSAs is a common 
occurrence when the complex has a high Kd and the complex is thus not very stable and dissociates 
(Hellman & Fried, 2007). The presence of the band corresponds to a protein- DNA complex on 
the EMSA’s (Fig 3.15) of the serine mutants along with the Far-UV circular dichroism and intrinsic 
fluorescence data all indicate that the mutant proteins are correctly folded and are capable of 
binding DNA. However, no binding for either mutant was observed when using ITC under the 
same conditions as the WT. This discrepancy can be explained because when using ITC, the high 
protein to DNA ratio used in EMSAs was not reached. In addition to this, in EMSAs there is a 
caging effect, which may stabilise the protein: DNA complex. This is because as the complex 
dissociates, the binding partners cannot diffuse away due to the gel matrix and may associate again 
quickly (Sidorova et al, 2010). ITC being a technique where molecules are free in solution rather 
than in a gel would not experience this phenomenon.  
 
Although S557A binding DNA was not observed using ITC the EMSA and fluorescence studies 
in the presence of DNA suggests that the S557A mutant binds with a greater affinity than the 
S557E mutant. In the EMSAs the protein-DNA complex is present for the S557A mutant at half 
the protein concentration required of the S557E mutant. Fluorescence studies in the presence of 
DNA resulted in quenching for all three proteins. The quenching effect was most noted in the WT, 
followed by the S557A mutant. DNA is known to quench fluorescence statically via direct base 
stacking or indirectly as a result of conformational changes (Lakowicz, 2006). As there are no 
tryptophans that interact directly with the DNA it is likely that the quenching is a result of a 
conformational change in the protein upon DNA binding. The amount of quenching may be related 
to DNA binding as more protein molecules bound to DNA would result in a greater quenching 
effect. The greater quenching of the S557A mutant in comparison to the S557E mutant indicates 
that the S557A mutant binds DNA with a greater affinity. 
 
The significantly decreased DNA binding affinity of the mutants compared to the WT alludes to 
the importance of Ser557 upon binding of the FHD to DNA. In the crystal structure of the WT 
FHD bound to Wang DNA (2A07), Ser557 on the monomeric FHD forms a hydrogen bond with 
the DNA backbone. The loss of this hydrogen bond in the S557A mutant would reduce the binding 
affinity to some degree which is observed. The S557E, mutant with its increased negative charge, 
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likely causes electrostatic repulsion which could prevent helix 3 from entering the major groove 
of the DNA to some extent. If Ser557 were phosphorylated, the bulk and greater negative charge 
would further inhibit DNA binding. This would be due to electrostatic repulsion between the 
negatively charged oxygen ions and the negatively charged DNA backbone. The increased bulk of 
a phosphate group would sterically inhibit helix 3 from entering the major groove of the DNA. 
 
To complement the DNA binding studies and try to obtain more detailed information about the 
possible changes in DNA binding of the FOXP2 FHD when Ser557 is phosphorylated, molecular 
docking studies were performed. The FHD in the crystal structure (2A07) was modified to produce 
S557E, S557A and phosphorylated WT models which were all subsequently docked to modelled 
Nelson DNA. The interactions in the interface of the models were analysed by looking at the 
number of hydrogen bonds, contacts and buried surface area. The docking studies complemented 
the EMSA and ITC data as they indicated that the S557E mutant has a decreased DNA binding 
affinity in comparison to the WT. The S557A mutant and the WT had the greatest buried surface 
areas and highest number of contacts compared to the S557E mutant and Phos-WT (Fig 3.16). 
This could indicate that the use of the phosphomimic, in this case, could give reliable information 
about phosphorylated FOXP2. Furthermore, the number of contacts, hydrogen bonds and buried 
surface area obtained from the docked models indicate that it is likely that the WT and S557A 
mutant bind at a stronger Kd than the S557E and Phos-WT. Interestingly a structural alignment of 
the docked models revealed that helix 3 in the phosphorylated model was not docked as deeply 
into the major grove of the DNA when compared to the WT. This suggests that the bulk and charge 
of the phosphate group prevents helix 3 from entering the major groove when serine 557 is 
phosphorylated thus inhibiting DNA binding. 
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CONCLUSION 
 
Serine 557 is a residue in the DNA binding helix of the FOXP2 FHD. A glutamate mutant (S557E) 
was used, alongside a control (S557A) to determine the possible effects that phosphorylation of 
this serine would have on the structure and DNA binding of the FOXP2 FHD. Both the glutamate 
and alanine mutants had conserved secondary and tertiary structure in comparison with the WT 
indicating that it is likely phosphorylation will not alter the secondary or tertiary structure of the 
FHD. Mutation of Ser557 does however prevent dimerisation of the FHD which highlights not 
only importance of the serine in maintaining the dimer but also indicates that phosphorylation 
could prevent domain swapping. Most notably, the S557E mutation showed significantly reduced 
DNA binding when compared to the WT FHD. This indicates that phosphorylation of Ser557 could 
disrupt DNA binding likely to due to electrostatic and steric hindrance. This shows that 
phosphorylation of Ser557 in the FOXP2 FHD could act as a control mechanism for FOXP2 and 
ultimately could be involved in regulation of transcription. 
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